BioAtla, Inc. (BCAB) Dividend History

BioAtla, Inc. (BCAB) is a biotechnology company focused on developing next-generation antibody-based therapeutics for cancer and other serious diseases. The company specializes in its proprietary AZCT (A priori, Target, and Location-Validated Antibody-Drug Conjugate) platform, which aims to create targeted treatments with improved safety and efficacy. BioAtla's pipeline includes innovative immuno-oncology and targeted therapy candidates.

11085 Torreyana Road, San Diego, CA, 92121
Phone: 858-558-0708
Website: https://www.bioatla.com

Dividend History

BioAtla, Inc. currently does not pay dividends

Company News

BioAtla to Participate in the Citizens Life Sciences Conference

BioAtla, a clinical-stage biotechnology company, announced that it will provide a corporate update and participate in investor meetings at the Citizens Life Sciences Conference in May 2025. The company also announced that it will report its Q1 2025 financial results on May 6, 2025.

GlobeNewswire Inc.
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla, a biotechnology company, announced that it will present a poster at the upcoming IASLC 2024 Hot Topic in Basic & Translational Science Meeting. The poster will focus on the characterization of mutated KRAS genotype and clinical outcomes in patients with advanced NSCLC treated with mecbotamab vedotin, a CAB-AXL-ADC.

GlobeNewswire Inc.
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla, a biotechnology company, announced that it will present an oral presentation on its novel conditionally active biologic (CAB) anti-CTLA-4 antibody at the upcoming Society for Melanoma Research 21st International Congress.

GlobeNewswire Inc.
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla, a biotechnology company, provided updates on its two clinical-stage assets, mecbotamab vedotin and evalstotug. Mecbotamab vedotin, targeting AXL, showed clinical benefit in non-small cell lung cancer patients with KRAS mutations. Evalstotug, a CTLA-4 antibody, demonstrated promising anti-tumor activity with a differentiated safety profile.

GlobeNewswire Inc.
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 07:28:28 UTC